SCHEMBL17951145

SCHEMBL17951145

Cc1ccc(S(=O)(=O)n2ccc3c(NN4CCCC(NC(=O)OC(C)(C)C)C4)ncnc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 2/20 0.41
▸ NAMPT P43490 2/20 0.39
▸ ALOX5AP P20292 1/20 0.38
▸ FEN1 P39748 1/20 0.38
▸ GPR119 Q8TDV5 3/20 0.37
▸ JAK3 P52333 2/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ BTK Q06187 1/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ BCHE P06276 1/20 0.36
▸ HTR6 P50406 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ ACVR1 Q04771 1/20 0.35
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28230643 0.90 MAPK1 (0.41) MAPK1USP2ALDH1A1LMNAEPHX2
SCHEMBL9929963 0.86 MAP4K4 (0.47) MAP4K4NAMPTALOX5APFEN1JAK3
SCHEMBL31124435 0.85 BTK (0.46) NAMPTGPR119JAK3BTKJAK2
SCHEMBL31124343 0.85 BTK (0.46) NAMPTGPR119JAK3BTKJAK2
SCHEMBL17951124 0.84 JAK2 (0.40) MAP4K4NAMPTALOX5APFEN1GPR119
SCHEMBL17951105 0.82 RAB9A (0.40) ALDH1A1POLBRAB9A
SCHEMBL19725939 0.82 GPR119 (0.42) NAMPTGPR119BCHEHTR6
SCHEMBL6128886 0.82 GPR119 (0.49) GPR119JAK3BTKJAK1BCHE
SCHEMBL2728373 0.82 GPR119 (0.49) GPR119JAK3BTKJAK1BCHE
SCHEMBL17545832 0.82 GPR119 (0.49) GPR119JAK3BTKJAK1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3248980-B1 JAK INHIBITOR WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) 2023-09-06 — — EP disclosed
US-10617690-B2 JAK inhibitor Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2020-04-14 — — US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 — — US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 — — US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 — — US disclosed
EP-3248980-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-11-29 — — EP disclosed
WO-2016116025-A1 JAK INHIBITOR 南京明德新药研发股份有限公司 2016-07-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360794-A1 JAK INHIBITOR JAK2, JAK1, JAK3 MAP4K4 150/4885NAMPT 1808/4885ALOX5AP 2510/4885
US-10617690-B2 JAK inhibitor JAK2, JAK1, JAK3 MAP4K4 150/4885NAMPT 1808/4885ALOX5AP 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback